GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2007

Introgen Receives European Certification of its Production Facilities

  • Gendux and Introgen Therapeutics say that they have been given the go ahead to produce its drug candidate for a variety of somatic and inherited cancer indications.

     

    Introgen received certification from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) and its facilities and production processes were found to be compliant with European Good Manufacturing Practices for the production of Advexin® p53 therapy.

     

    After an audit and inspection of Introgen’s facilities, clinical certification by the MHRA was obtained so that Advexin can be made available to cancer patients in the E.U. Introgen will supply Gendux and its European marketing partners with Advexin.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?